NCT04866563View on ClinicalTrials.gov

A Study of Efficacy and Safety of AX-8 in Chronic Cough

PHASE2CompletedINTERVENTIONAL
Enrollment

108

Participants

Timeline

Start Date

August 11, 2021

Primary Completion Date

June 16, 2025

Study Completion Date

June 16, 2025

Conditions
Chronic Cough
Interventions
DRUG

AX-8, Part 1 of the study

orally disintegrating tablets, BID

DRUG

Placebo, Part 1 of the study

orally disintegrating tablets, BID

DRUG

AX-8, Part 2 of the study

orally disintegrating tablets, TID

DRUG

Placebo, Part 2 of the study

orally disintegrating tablets, TID

Trial Locations (16)

B9 5SS

Axalbion Study Site 4406, Birmingham

DN20 0HR

Axalbion Study Site 4404, Broughton

CM1 7ET

Axalbion Study Site 4409, Chelmsford

CV3 4FJ

Axalbion Study Site 4413, Coventry

SE5 9RS

Axalbion Study Site 4401, London

SW3 6HP

Axalbion Study Site 4402, London

W2 1NY

Axalbion Study Site 4410, London

M23 9LT

Axalbion Study Site 4403, Manchester

NE29 8NH

Axalbion Study Site 4405, North Shields

BR5 3QG

Axalbion Study Site 4417, Orpington

OX3 9DU

Axalbion Study Site 4407, Oxford

PR2 9HT

Axalbion Study Site 4411, Preston

BD18 3SA

Axalbion Study Site 4412, Shipley

NP20 2EF

Axalbion Study Site 4408, Newport

BT9 7AB

Axalbion Study Site 4414, Belfast

HA6 2RN

Axalbion Study Site 4415, Northwood

All Listed Sponsors
lead

Axalbion SA

INDUSTRY

NCT04866563 - A Study of Efficacy and Safety of AX-8 in Chronic Cough | Biotech Hunter | Biotech Hunter